A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
The purpose of this study is to determine the predictive value of a model of Nomogram
 Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.
Inclusion Criteria:

 -  histologically confirmed diagnosis of CD20+ DLBCL

 Exclusion Criteria:

 -  primary central nervous system lymphoma

 -  "double-hit" lymphoma